HK1042230A1 - Methods of inhibiting resorption in bone - Google Patents

Methods of inhibiting resorption in bone Download PDF

Info

Publication number
HK1042230A1
HK1042230A1 HK02101656.1A HK02101656A HK1042230A1 HK 1042230 A1 HK1042230 A1 HK 1042230A1 HK 02101656 A HK02101656 A HK 02101656A HK 1042230 A1 HK1042230 A1 HK 1042230A1
Authority
HK
Hong Kong
Prior art keywords
dosing
unit dosage
bisphosphonate
alendronate
weekly
Prior art date
Application number
HK02101656.1A
Other languages
English (en)
Chinese (zh)
Inventor
G. Daifotis Anastasia
C. Santora Ii Arthur
A. Yates John
Original Assignee
Merck Sharp & Dohme Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27451690&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1042230(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9717590.5A external-priority patent/GB9717590D0/en
Priority claimed from GBGB9717850.3A external-priority patent/GB9717850D0/en
Application filed by Merck Sharp & Dohme Corp. filed Critical Merck Sharp & Dohme Corp.
Publication of HK1042230A1 publication Critical patent/HK1042230A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Saccharide Compounds (AREA)
  • Fittings On The Vehicle Exterior For Carrying Loads, And Devices For Holding Or Mounting Articles (AREA)
  • Pit Excavations, Shoring, Fill Or Stabilisation Of Slopes (AREA)
  • Aiming, Guidance, Guns With A Light Source, Armor, Camouflage, And Targets (AREA)
HK02101656.1A 1997-07-22 2002-03-04 Methods of inhibiting resorption in bone HK1042230A1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US5335197P 1997-07-22 1997-07-22
US5353597P 1997-07-23 1997-07-23
GBGB9717590.5A GB9717590D0 (en) 1997-08-20 1997-08-20 Oral method for treating or preventing abnormal bone resorption
GB9717590 1997-08-20
GB9717850 1997-08-22
GBGB9717850.3A GB9717850D0 (en) 1997-08-22 1997-08-22 Oral method for treating or preventing abnormal bone resorption

Publications (1)

Publication Number Publication Date
HK1042230A1 true HK1042230A1 (en) 2002-08-09

Family

ID=27451690

Family Applications (4)

Application Number Title Priority Date Filing Date
HK02101656.1A HK1042230A1 (en) 1997-07-22 2002-03-04 Methods of inhibiting resorption in bone
HK02101869.4A HK1042232A1 (en) 1997-07-22 2002-03-12 Methods of inhibiting resorption in bone
HK02102042.2A HK1040494A1 (en) 1997-07-22 2002-03-16 Methods of inhibiting resorption in bone
HK02102043.1A HK1040495A1 (en) 1997-07-22 2002-03-16 Methods of inhibiting resorption in bone

Family Applications After (3)

Application Number Title Priority Date Filing Date
HK02101869.4A HK1042232A1 (en) 1997-07-22 2002-03-12 Methods of inhibiting resorption in bone
HK02102042.2A HK1040494A1 (en) 1997-07-22 2002-03-16 Methods of inhibiting resorption in bone
HK02102043.1A HK1040495A1 (en) 1997-07-22 2002-03-16 Methods of inhibiting resorption in bone

Country Status (31)

Country Link
EP (5) EP1132088A3 (enExample)
JP (2) JP3479780B2 (enExample)
KR (3) KR100391732B1 (enExample)
CN (3) CN1299689C (enExample)
AT (2) ATE209037T1 (enExample)
AU (1) AU8493698A (enExample)
BG (1) BG66282B1 (enExample)
BR (1) BR9810779A (enExample)
CA (1) CA2294595C (enExample)
CY (2) CY1107535T1 (enExample)
DE (6) DE122006000009I1 (enExample)
DK (2) DK1175904T3 (enExample)
EA (1) EA004544B2 (enExample)
EE (1) EE05603B1 (enExample)
ES (3) ES2253136T1 (enExample)
HK (4) HK1042230A1 (enExample)
ID (1) ID24096A (enExample)
IL (1) IL133535A0 (enExample)
IS (3) IS5315A (enExample)
LU (2) LU91222I2 (enExample)
NL (2) NL300223I1 (enExample)
NO (1) NO20000323L (enExample)
NZ (1) NZ501807A (enExample)
PL (1) PL195272B1 (enExample)
PT (2) PT998292E (enExample)
SG (2) SG109478A1 (enExample)
SI (1) SI0998292T1 (enExample)
SK (1) SK932000A3 (enExample)
TR (1) TR200000145T2 (enExample)
UY (1) UY25950A1 (enExample)
WO (1) WO1999004773A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1798700A (en) 1998-12-25 2000-07-31 Yamanouchi Pharmaceutical Co., Ltd. Medicinal compositions for treating osseous lesion in multiple myeloma
ATE293450T1 (de) * 1999-05-21 2005-05-15 Novartis Pharma Gmbh Verwendung von biphosphonsäuren zur behandlung von angiogenese
DE60043648D1 (de) * 1999-07-19 2010-02-25 Toray Industries Medikamente zur behandlung von periodontalen erkrankungen
AU2580001A (en) 1999-12-20 2001-07-03 Merck & Co., Inc. Blister package for pharmaceutical treatment card
AU2270101A (en) * 1999-12-20 2001-07-03 Merck & Co., Inc. Pharmaceutical kit
AU2001251432A1 (en) * 2000-04-07 2001-10-23 The Board Of Regents Of The University Of Texas System Unique compositions of zwitterionic phospholipids and bisphosphonates and use ofthe compositions as bisphosphate delivery systems with reduced gi toxicity
IL153229A0 (en) 2000-06-20 2003-07-06 Novartis Ag Method of administering bisphosphonates
SI1296689T1 (sl) * 2000-06-20 2006-08-31 Novartis Ag Nacin dajanja pacientu bisfosfonatov
US6638920B2 (en) * 2000-07-21 2003-10-28 Merck & Co., Inc. Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses
SE0101379D0 (sv) 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
CN100345549C (zh) * 2001-05-02 2007-10-31 诺瓦提斯公司 包含双膦酸的药用吸入组合物
KR20140021045A (ko) * 2002-05-10 2014-02-19 에프. 호프만-라 로슈 아게 골다공증 치료 및 예방용 비스포스폰산
SE0203065D0 (sv) * 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
NZ545804A (en) * 2003-09-19 2009-09-25 Wisconsin Alumni Res Found Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-or-vitamin D derivatives and a bisphosphonate
JPWO2005072747A1 (ja) * 2004-02-02 2007-09-13 小野薬品工業株式会社 骨吸収抑制剤
JP2009508834A (ja) * 2005-09-16 2009-03-05 セラマイン リミテッド ビスホスホネート製剤
WO2012078528A2 (en) * 2010-12-06 2012-06-14 Effrx Pharmaceuticals Sa Stable effervescent bisphosphonate formulations with rapid solubilization characteristics
CN106924257B (zh) * 2017-03-14 2019-11-19 湖南赛隆药业有限公司 质子泵抑制剂和抗骨质疏松药的复合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL84731A0 (en) * 1986-12-19 1988-05-31 Norwich Eaton Pharma Heterocycle-substituted diphosphonic acids and salts and esters and pharmaceutical compositions containing them
SE8704436D0 (sv) * 1987-11-13 1987-11-13 Pm Konsult Handelsbolag Anvendning av antisekretoriska substanser for nya indikationer
ES2074769T3 (es) * 1991-07-01 1995-09-16 Gergely Gerhard Procedimiento para la elaboracion de un preparado farmaceutico con, al menos, dos principios activos diferentes y uso de un preparado de este tipo.
DE69231313T2 (de) * 1991-11-22 2001-03-15 Procter & Gamble Pharmaceuticals, Inc. Risedronat enthaltende Arzneimittel mit verzögerter Wirkstoffabgabe
US5270365A (en) * 1991-12-17 1993-12-14 Merck & Co., Inc. Prevention and treatment of periodontal disease with alendronate
US5294433A (en) * 1992-04-15 1994-03-15 The Procter & Gamble Company Use of H-2 antagonists for treatment of gingivitis
JP4481368B2 (ja) * 1992-06-30 2010-06-16 味の素株式会社 骨粗鬆症の治療用のためのホスホネート類の用途
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
JPH11506750A (ja) * 1995-06-06 1999-06-15 メルク エンド カンパニー インコーポレーテッド 慢性関節リウマチに係わる骨欠損に対するビスホスホネート療法
ES2210529T3 (es) * 1996-05-17 2004-07-01 MERCK & CO., INC. Formulacion de bisfosfonato efervescente.

Also Published As

Publication number Publication date
EP0998292B1 (en) 2001-11-21
CY2007022I2 (el) 2012-01-25
ES2269014T1 (es) 2007-04-01
DE01201911T1 (de) 2007-10-18
CN1166365C (zh) 2004-09-15
HK1042232A1 (en) 2002-08-09
DE122006000009I1 (de) 2006-06-14
CY2007022I1 (el) 2012-01-25
KR20010022110A (ko) 2001-03-15
IL133535A0 (en) 2001-04-30
KR100391732B1 (ko) 2003-07-16
PL338635A1 (en) 2000-11-06
EE05603B1 (et) 2012-12-17
NO20000323D0 (no) 2000-01-21
SG139556A1 (en) 2008-02-29
PT1175904E (pt) 2007-04-30
ES2164447T3 (es) 2002-02-16
DE122007000063I1 (de) 2007-12-20
UY25950A1 (es) 2000-09-29
SG109478A1 (en) 2005-03-30
JP2002502433A (ja) 2002-01-22
EP1151752A3 (en) 2002-12-18
DE69803291D1 (de) 2002-02-21
EA200000151A1 (ru) 2000-10-30
ATE209037T1 (de) 2001-12-15
BG66282B1 (bg) 2013-01-31
HK1040494A1 (en) 2002-06-14
EP1175904B8 (en) 2007-05-09
SK932000A3 (en) 2000-09-12
PL195272B1 (pl) 2007-08-31
DE01201913T1 (de) 2007-02-08
NL300223I1 (nl) 2006-04-03
CN1299689C (zh) 2007-02-14
EP1132088A3 (en) 2002-04-24
IS7230A (is) 2004-04-21
HK1040495A1 (en) 2002-06-14
BR9810779A (pt) 2000-07-25
NO20000323L (no) 2000-03-20
NZ501807A (en) 2003-02-28
CA2294595C (en) 2001-08-21
SI0998292T1 (en) 2002-04-30
DE69803291T2 (de) 2002-08-08
DK0998292T3 (da) 2002-05-13
PT998292E (pt) 2002-04-29
NL300292I1 (nl) 2007-11-01
DE69837450D1 (de) 2007-05-10
WO1999004773A9 (en) 1999-10-28
CA2294595A1 (en) 1999-02-04
EP0998292A2 (en) 2000-05-10
WO1999004773A2 (en) 1999-02-04
CY1107535T1 (el) 2012-01-25
EA004544B1 (ru) 2004-06-24
EP1175903A2 (en) 2002-01-30
LU91222I2 (fr) 2006-04-18
EP1151752A2 (en) 2001-11-07
HK1024166A1 (en) 2000-10-05
IS7231A (is) 2004-04-21
CN1265035A (zh) 2000-08-30
DK1175904T3 (da) 2007-05-07
EE200000040A (et) 2000-10-16
JP2005068010A (ja) 2005-03-17
WO1999004773A3 (en) 1999-04-15
EA004544B2 (ru) 2006-12-29
KR20030097610A (ko) 2003-12-31
CN1602879A (zh) 2005-04-06
BG104093A (en) 2000-10-31
AU8493698A (en) 1999-02-16
EP1175904B1 (en) 2007-03-28
ATE357921T1 (de) 2007-04-15
EP1175903A3 (en) 2002-12-18
EP1132088A2 (en) 2001-09-12
ID24096A (id) 2000-07-06
ES2253136T1 (es) 2006-06-01
CN1602880A (zh) 2005-04-06
TR200000145T2 (tr) 2000-05-22
EP1175904A3 (en) 2002-12-18
JP3479780B2 (ja) 2003-12-15
EP1175904A2 (en) 2002-01-30
IS5315A (is) 1999-12-21
ES2269014T3 (es) 2007-05-01
LU91364I2 (fr) 2007-11-12
DE69837450T2 (de) 2007-08-23
KR20030097611A (ko) 2003-12-31

Similar Documents

Publication Publication Date Title
US6225294B1 (en) Method for inhibiting bone resorption
US6015801A (en) Method for inhibiting bone resorption
US6432932B1 (en) Method for inhibiting bone resorption
CA2294595C (en) Inhibiting bone resorption
GB2336311A (en) Bisphosphonate Dosing Regimen
AU741818B2 (en) Method for inhibiting bone resorption
CA2349733A1 (en) Inhibition bone resorption
AU2451102A (en) Method for inhibiting bone resorption
AU1567702A (en) Method for inhibiting bone resorption
AU2005227418A1 (en) Method for inhibiting bone resorption
IL153109A (en) An effective pharmaceutical composition for inhibiting bone resorption in humans containing alendronic acid or its acceptable pharmaceutical salt or mixture
MXPA00000789A (en) Method for inhibiting bone resorption
HK1024166B (en) Method for inhibiting bone resorption